Navigation Links
Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies
Date:5/26/2009

ATLANTA, May 26 /PRNewswire/ -- Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED), will be available in U.S. pharmacies by the first week of June 2009. Vimpat was approved by the U.S. FDA in the fall of 2008 for the use as an add-on therapy for the treatment of partial-onset seizures in people 17 years and older with epilepsy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22555 )

Vimpat approval is based on safety and efficacy data from three pivotal trials with approximately 1,300 patients. In the studies, many patients taking Vimpat had their seizures reduced by half or more and experienced reductions in median seizure frequency at rates that were significantly greater than those in the placebo group. Across the pivotal trials, 2.7% of the patients taking 200 mg/day and 3.3% of patients taking 400 mg/day of Vimpat were seizure free throughout the 12-week maintenance phase, vs. 0.9% of placebo patients.

Vimpat demonstrated efficacy and safety when combined with a broad range of existing AEDs.

Vimpat is available in 50, 100, 150, and 200 mg strengths, and as an IV infusion. Formulations can be used interchangeably at equivalent dosing. Vimpat should be taken twice daily; the daily dose should not exceed 400 mg.

In clinical trials, treatment-related adverse events were mostly characterized as "mild" or "moderate" in severity and included dizziness, headache, diplopia, and nausea.

Epilepsy is a chronic neurological disorder affecting approximately three million people in the U.S.

  • Epilepsy can affect anyone at any time; it is a common neurological condition that can be life long
  • Less than half (47%) will attain seizure control with the first AED
  • More than 30% will continue to experience seizures despite trying two or more AEDs
  • 200,000 new cases are diagnosed each year, a number that is expected to grow at a faster rate as the population ages

Important safety information about Vimpat in the U.S.

Vimpat tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

For more information, and prescribing information visit www.Vimpat.com or contact UCB at (800) 477-7877.

Vimpat(R) is a registered trademark under license from Harris FRC Corporation.

    For further information
    Andrea Levin, Public Relations Manager, CNS, UCB
    Phone: 770-970-8352
    Email: andrea.levin@ucb.com

    Sarah Handza, Cooney Waters Group
    Phone: 212-886-2206
    Email: shandza@cooneywaters.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.6 billion Euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
2. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. ValueRich Report on AMDL/China Available on Web Site
5. AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
6. Arpida-Supported CME Symposium Available Online
7. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
8. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
9. Neogen Launches Quickest Test Available for Tetracyclines in Milk
10. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
11. Canadas Best-Selling Soymilk Now Available with Marteks lifesDHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017  Market researcher Kalorama Information ... article regarding the telemedicine market.  The telemedicine ... Information.  The article, "Heart and Asthma ...  used information from Kalorama Information,s Remote Patient ... Market  (Sleep, Diabetes, Vital Signs /EKG ...
(Date:8/10/2017)... Warsaw, Indiana (PRWEB) , ... August 09, 2017 ... ... is equipped to help the agriculture industry reach its ideal customers with the ... across the nation. , “As a Midwest company, we realize how crucial the ...
(Date:8/10/2017)... ... 09, 2017 , ... Okyanos Center for Regenerative Medicine has announced its First ... in Freeport, Grand Bahama on September 27, 2017. This daytime event is free to ... the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) and regulations laid out ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... news outlet had initiated coverage on Next Group Holdings, Inc. and see's significant ... markets geared toward those that cannot engage in traditional banking services. According to ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):